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 BNCT is a targeted, tumor cell-selective and binary radiation therapy based upon the very facile capture of a neutron by the 10B nucleus. 
 The 10B nucleus captures slow neutrons much more easily than elements found in the human body.
 The 7Li3+ and 4He2+ ions have short trajectories in tissue (one cell diameter) and create ionization damage in cancer cells, notably DNA double-strand breaking.
 10B is selectively delivered to cancer cells by various means (targeting tumor cell receptors with liposomes and related nanoparticles) prior to neutron irradiation.
 Target compounds containing 10B must be delivered selectively to cancer cells to provide one billion (109) 10B-atoms per cancer cell (30 g 10B/g tumor).
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Oligomeric Phosphate Diester (OPD) Nanoparticles
 OPDs derived from carborane diols may be prepared using solid 
phase synthesis or in solution (bench top).
 The structural variety of available diols coupled to the ease of 
linking OPDs to other functional structures ensures a wide range
of properties (size, charge, lipophilicity, conjugation with reactive
species and biomolecules such as DNA, peptides, folic acid, etc.).
Biodistribution of a Typical OPD in Mice Bearing 
Breast Cancer (EMT6) Tumors
Delocalization of B in cellular nucleus greatly enhances BNCT efficacy
Fluorescence Labeled OPD Microinjected in 
TC7 African Monkey Kidney Cells
Photo taken 20 min following microinjection into cell
cytoplasm, with OPDs in cell nucleus.
100 µM Solution of OPD
3 ☓ 10 10 ml injection
1 ☓ 109 B-atom/cell
Liposomes as Nanoparticle Delivery Vehicles
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Typical Liposome Constituents and Structure 
Lecithin
(phosphatidylcholine)
Biodistribution of Liposomes Containing Aqueous 
Na3[a
2-B20H17(en)] in BALB/c Mice Bearing Breast 
Cancer (EMT6) Tumors
internal aqueous space
bilayer membrane with cholesterol 
added for structural reinforcement
Liposomes have demonstrated the ability to accumulate in
tumors in high concentration relative to normal tissues, including 
blood if they are sufficiently small (30 120 nm diameter).
OPD Nanoparticles (Micelles)
 When dissolved in water (or blood plasma) OPD’s are coiled into small 
nanoparticles (micelles).
 The plasma membrane of cells may be penetrated by liposomes (30 120 
nm diameter nanoparticles) which encapsulate a large number of OPD
micelles (0.5 3 nm diameter) in their aqueous core.
 The liposome carriers selectively target cancer cells by attached 
cancer cell-selective bioligands such as cancer associated antibodies.
 Once inside the cancer cell liposomes rupture and release OPD in the 
cell interior (cytoplasm) followed by OPD migration to the cell nucleus, 
association with genetic DNA and certain cell death from BNCT.
1) Coiling of OPD in water or blood plasma
2) Encapsulation of OPD micelles in liposome with attachment of bioligands
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Uncoiled and less stable 
structure of OPD Coiled OPD micelle stabilized 
by surface charges 
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Injected Dose: 9 mg B/kg body wt.
Injected Dose: 5 mg B/kg body wt.
0.5 3 nm
Liposomes containing OPDs;Healthy cell; Cancer cell; Antigen; Antibody
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